Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rami Komrokji

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Blood|August 5, 2017
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNElias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology|August 4, 2018
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort studyAshley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
Blood|October 15, 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAshley A Basiorka, Kathy L McGraw, Erika A Eksioglu, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib ResultsNaval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Blood|August 5, 2017
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNElias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology|August 4, 2018
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort studyAshley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
Blood|October 15, 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAshley A Basiorka, Kathy L McGraw, Erika A Eksioglu, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib ResultsNaval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
Pageof 13